Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Alpert, J.S.
Right arrow Articles by Henry, T.D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Alpert, J.S.
Right arrow Articles by Henry, T.D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Issues in antithrombin therapy for UA/NSTEMI

J.S. Alpert*,1, A.J. Budaj2, E.P. Gurfinkel3 and T.D. Henry4

1 University of Arizona College of Medicine, Tucson, Arizona, USA
2 Postgraduate Medical School, Warsaw, Poland
3 Favoloro Foundation, Buenos Aires, Argentina
4 Hennepin County Medical Center, Minneapolis, Minnesota, USA

* Correspondence: Joseph S. Alpert, University of Arizona College of Medicine, Tucson, Arizona, USA

Abstract

In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIa antagonists would be helpful, as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization.

Key Words: Unstable angina • antithrombin • heparin • low-molecular-weight heparin • guidelines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.